Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Clinical trial NCT04934800 · COMPLETED

Trial details

NCT number: NCT04934800
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Study type: OBSERVATIONAL

Multiple Sclerosis

Start date: 2019-12-10
Primary completion: 2024-05-20
Enrollment: 256

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.